Does MDwise Cover Cialis? Coverage Rules, Costs, and What to Do If Denied

What Is MDwise and How Does Its Drug Coverage Work?

MDwise is an Indiana-based Medicaid managed-care organization that contracts with the Indiana Family and Social Services Administration (FSSA) to provide Hoosier Care Connect, Hoosier Healthwise, and other Medicaid programs to eligible low-income residents. Like all Medicaid managed-care plans, MDwise uses a formulary, a tiered list of covered drugs, to control pharmacy spending.

The Formulary Tier System

Medicaid formularies in Indiana follow a tiered structure where Tier 1 drugs (usually generics) carry the lowest cost-sharing, and higher tiers carry larger copays or require additional authorization steps. Brand-name Cialis, which carries a retail price exceeding $400 per month, sits outside standard Medicaid coverage in most states because the FDA approved generic tadalafil in 2018, making the brand version a non-preferred option. The FDA granted first generic approval for tadalafil 2.5 mg, 5 mg, 10 mg, and 20 mg tablets to Lilly ICOS's patent expiration in September 2018 [1].

Federal Rules That Shape Coverage

Federal Medicaid law under 42 CFR §440.120 gives states flexibility to set their own formulary restrictions, including exclusions for drugs "used for anorexia, weight gain, fertility, cosmetic purposes, erectile dysfunction, or hair growth" unless medically necessary for a non-excluded condition [2]. Indiana's Medicaid program, administered partly through MDwise, uses this authority. Sildenafil and tadalafil prescribed purely for erectile dysfunction without a co-occurring covered condition frequently face denial at the formulary level.

Is Tadalafil (Generic Cialis) Covered by MDwise?

Generic tadalafil occupies a different coverage position than brand Cialis. Some MDwise plans include tadalafil on formulary for specific diagnoses, particularly benign prostatic hyperplasia (BPH) and pulmonary arterial hypertension (PAH). ED-only prescriptions face stricter scrutiny.

Coverage by Diagnosis: ED vs. BPH vs. PAH

The FDA approved tadalafil 5 mg daily for the treatment of signs and symptoms of BPH in 2011, and for simultaneous treatment of both ED and BPH in the same year [3]. This clinical distinction matters enormously for coverage:

• Erectile dysfunction (ICD-10: N52.xx): Medicaid exclusions apply most directly here. Expect denial or prior authorization requirements.
• Benign prostatic hyperplasia (ICD-10: N40.1): Tadalafil 5 mg daily has a legitimate medical-necessity argument. Some Medicaid plans cover it under this diagnosis when alpha-blockers have been inadequate.
• Pulmonary arterial hypertension (ICD-10: I27.0): Tadalafil 20 mg (brand: Adcirca, generic available) is a first-line PAH therapy and covered by nearly all plans, including Medicaid, under this diagnosis.

A 2021 analysis published in the Journal of Managed Care and Specialty Pharmacy found that tadalafil coverage rates on Medicaid formularies varied from 12% to 67% depending on the diagnosis attached to the claim [4]. That range reflects exactly how much diagnosis coding affects real-world access.

Step Therapy Requirements

Even when tadalafil appears on formulary, MDwise may require step therapy, meaning the prescriber must document that the patient tried and failed sildenafil (generic Viagra) first. Sildenafil costs as little as $10 for 30 tablets at discount pharmacies [5], so insurers often mandate it as the first-line PDE5 inhibitor. If a patient cannot tolerate sildenafil due to side effects (most commonly headache, flushing, or visual disturbances reported in up to 11% of users in clinical trials [6]), that intolerance can be documented to bypass the step-therapy requirement.

Prior Authorization for Tadalafil Through MDwise

Prior authorization (PA) is the single biggest barrier most patients encounter. The prescriber, not the patient, submits the PA request, but patients who understand the process can help their providers submit stronger documentation.

What Information the PA Requires

A complete PA request for tadalafil through MDwise typically includes:

• The patient's confirmed diagnosis with ICD-10 code
• Documentation of the duration and severity of symptoms
• Names and dates of previously tried medications (step therapy record)
• Reason tadalafil is preferred over sildenafil (e.g., desired 36-hour window, daily dosing for BPH)
• Lab values if relevant (testosterone level, PSA if BPH diagnosis)

The American Urological Association (AUA) 2018 guideline on erectile dysfunction states: "Shared decision-making should guide treatment selection, and oral PDE5 inhibitors are recommended as first-line therapy for most men with ED" [7]. Citing this AUA language in a PA letter strengthens the medical-necessity argument.

Turnaround Time and Urgent Requests

Standard PA requests through Indiana Medicaid managed-care plans must receive a decision within 14 days under 42 CFR §438.210(d)(1) [8]. Expedited requests, when a provider certifies that waiting 14 days could jeopardize health, must be resolved within 72 hours. Most tadalafil requests for ED are processed under the standard timeline.

Common Reasons for PA Denial

The most frequent denial reasons include:

• Diagnosis coded as ED without documentation of medical necessity
• No documented sildenafil trial
• Prescribing outside the FDA-approved indication
• Formulary exclusion for lifestyle or elective medications

If MDwise denies the PA, the denial notice must explain the reason and include appeal instructions per 42 CFR §438.408 [9].

What Tadalafil Actually Costs Without Coverage

If MDwise denies coverage entirely, generic tadalafil is one of the more affordable specialty-adjacent drugs on the cash market.

Cash-Pay Pricing at Major Pharmacies

At GoodRx-negotiated rates as of early 2025:

• Tadalafil 10 mg, 30 tablets: approximately $18, $35
• Tadalafil 20 mg, 30 tablets: approximately $22, $55
• Tadalafil 5 mg, 30 tablets (daily dose for BPH/ED): approximately $15, $40

These figures are consistent with FDA data on generic drug price reductions, which show that first-generic approvals cut brand-drug costs by a median of 80 to 85% within 12 months [10].

Manufacturer Patient Assistance Programs

Eli Lilly discontinued most branded Cialis patient assistance programs after generic entry. However, if a patient specifically needs brand Cialis for a documented clinical reason (rare), NeedyMeds.org and the Lilly Cares Foundation maintain contact information for case-by-case review.

How to Appeal an MDwise Coverage Denial

A denial is not the end of the road. Indiana Medicaid managed-care enrollees have a structured appeal process with defined timelines.

Step 1: Internal Appeal to MDwise

File a written internal appeal within 30 days of receiving the denial notice. The appeal should include:

• A cover letter from the prescribing provider explaining medical necessity
• Relevant clinical records (lab results, visit notes)
• Published guideline citations supporting the treatment choice (AUA, Endocrine Society)
• Documentation of any prior drug failures

MDwise must resolve standard internal appeals within 30 days. Expedited appeals must be resolved within 72 hours.

Step 2: State Fair Hearing

If MDwise upholds the denial, the patient may request a State Fair Hearing through Indiana's FSSA within 120 days of the internal appeal decision. An administrative law judge reviews the case independently. Research on Medicaid appeals shows that beneficiaries who submit appeals with physician-authored letters overturn denials at a rate of approximately 39 to 47% at the fair-hearing stage [11].

Step 3: External Independent Review

For certain denials categorized as medical-necessity decisions, Indiana law entitles enrollees to an external independent medical review conducted by a board-certified clinician not affiliated with MDwise.

Tadalafil for BPH: A Separate and Often Easier Coverage Path

Men who have both ED and BPH should discuss the dual-indication with their provider. The BPH treatment pathway frequently encounters less resistance on Medicaid formularies.

Clinical Evidence for Tadalafil in BPH

The key Phase 3 trial for tadalafil 5 mg in BPH (N=1,058) showed statistically significant improvement in International Prostate Symptom Score (IPSS) of 3.8 points versus 1.7 points for placebo at 12 weeks (P<0.001) [12]. This level 1 evidence supports medical-necessity arguments in PA letters.

The AUA BPH guideline (2021 update) lists PDE5 inhibitors as appropriate monotherapy for men with BPH and ED who prefer an oral agent: "Tadalafil 5 mg once daily is an appropriate treatment option for men with LUTS/BPH, particularly those with concurrent ED" [13].

Coding Strategy

Prescribers who submit tadalafil 5 mg claims under N40.1 (BPH with urinary obstruction) alongside N52.xx rather than ED alone may see improved approval rates. This is not "upcoding"; it is accurate documentation of co-existing conditions both addressed by the prescribed drug.

The HealthRX PA Decision Framework for Tadalafil Through Medicaid:

1. Confirm all active diagnoses (ED, BPH, PAH) and code them all on the claim.
2. Document sildenafil trial or intolerance before submitting PA.
3. Include AUA or Endocrine Society guideline language in the PA letter.
4. Request expedited review only if clinical urgency is genuine; false urgency claims delay future requests.
5. If denied, file the internal appeal within 30 days with physician-authored clinical narrative.
6. Use cash-pay generic tadalafil ($15, $55/month) as a bridge during appeal.

Sildenafil vs. Tadalafil: Which Is Easier to Get Covered?

For patients whose only goal is accessing a PDE5 inhibitor, sildenafil is the more accessible option on nearly every Medicaid formulary, including MDwise plans.

Formulary Position Comparison

Sildenafil (generic Viagra) received FDA approval for ED in 1998 [14] and generic approval in 2017, giving it a longer generic history and lower cost basis. Most Medicaid plans place it at Tier 1 or Tier 2 without prior authorization for ED. Tadalafil, with its 2018 generic entry, is often Tier 2 or Tier 3 and more frequently requires PA.

Clinical Differences That Justify Tadalafil

The primary pharmacokinetic difference is half-life. Sildenafil has a half-life of approximately 4 hours; tadalafil's half-life is 17.5 hours, supporting its "weekend pill" reputation and its suitability for daily dosing [15]. Men who prefer spontaneity or who have BPH symptoms requiring daily therapy have a clinically grounded reason to request tadalafil specifically, which the prescriber can document to support a non-formulary PA.

A meta-analysis in the European Urology journal (N=5,369 across 14 trials) found that daily tadalafil 5 mg produced significantly greater improvements in IPSS scores than on-demand sildenafil in men with both BPH and ED (mean difference 2.1 points, 95% CI 1.3 to 2.9) [16], providing evidence that they are not clinically interchangeable for the dual-indication population.

Telehealth and HealthRX: Accessing Tadalafil With or Without MDwise Coverage

Many patients find that a telehealth visit resolves the coverage problem faster than navigating MDwise's internal processes alone.

What a Telehealth Provider Can Do

A HealthRX-affiliated clinician can:

• Evaluate all co-existing diagnoses to identify the strongest coverage pathway
• Write a PA letter that cites current AUA and FDA labeling
• Prescribe generic tadalafil directly to a cash-pay pharmacy if insurance denial is expected
• Order relevant labs (testosterone, PSA) to strengthen medical-necessity documentation

Cash-Pay Telehealth as a Practical Alternative

Generic tadalafil at $15, $55 per month is within reach for many patients, particularly given that MDwise Medicaid copays for covered drugs are $0, $3 per fill in Indiana. The cost gap between covered and cash-pay generic tadalafil is often smaller than patients assume.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism notes: "We recommend treating symptomatic androgen-deficient men to achieve normal serum testosterone concentrations," and separately acknowledges that ED in the context of low testosterone may require both testosterone therapy and a PDE5 inhibitor for optimal response [17]. Men with documented low testosterone and ED have two overlapping medical justifications for treatment, both of which can be documented in a PA request.

Key Facts About Tadalafil Safety and Contraindications

Before pursuing any coverage pathway, patients and providers need to confirm that tadalafil is clinically appropriate.

Absolute Contraindications

The FDA-approved labeling for tadalafil lists the following absolute contraindications [18]:

• Concurrent use of any organic nitrate (nitroglycerin, isosorbide mononitrate or dinitrate) due to risk of severe hypotension
• Concurrent use of soluble guanylate cyclase stimulators (riociguat)
• Known hypersensitivity to tadalafil or any component of the formulation

Common Adverse Effects

In the Phase 3 trials supporting FDA approval, the most common adverse effects of tadalafil 20 mg were headache (15%), dyspepsia (10%), back pain (6%), myalgia (5%), and nasal congestion (4%) [19]. These rates were dose-dependent and generally mild to moderate in severity.

Patients with cardiovascular disease should undergo assessment per the Princeton Consensus guidelines before initiating any PDE5 inhibitor, as sexual activity itself carries metabolic demand equivalent to climbing two flights of stairs [20].